Key result
Anti-PCSK9 vaccines show potential to induce durable immune responses with lipid-lowering and anti-atherosclerotic effects in experimental and early clinical studies.
Why the study?
Despite available lipid-lowering drugs, achieving satisfactory control of lipid disorders remains challenging, creating a need for novel approaches to improve treatment adherence.
Anti-PCSK9 vaccines offer a promising approach for long-term LDL-C reduction with infrequent dosing, potentially overcoming adherence issues in ASCVD prevention.
No takes yet. Share an insight, caveat, or question.
Supports earlier intensive LDL-C lowering to curb ASCVD; leaves open optimal timing and duration in primary prevention.
Surma et al. (2024) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and Lipid disorders. Anti-PCSK9 vaccines was evaluated. Anti-PCSK9 vaccines show potential to induce durable immune responses with lipid-lowering and anti-atherosclerotic effects in experimental and early clinical studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: